Do analysts prefer MOR or GLAS?

Glass House Brands has a consensus target price of $16.00, suggesting a potential upside of 103.30%. Given Glass House Brands' stronger consensus rating and higher probable upside, analysts clearly believe Glass House Brands is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Glass House Brands 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, MOR or GLAS?

Glass House Brands has lower revenue, but higher earnings than MorphoSys. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A Glass House Brands N/A N/A N/A N/A N/A

Do analysts recommend RGC or GLAS?

Glass House Brands has a consensus price target of $16.00, suggesting a potential upside of 103.30%. Given Glass House Brands' stronger consensus rating and higher probable upside, analysts clearly believe Glass House Brands is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Glass House Brands 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, RGC or GLAS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Glass House Brands N/A N/A N/A N/A N/A

Is RGC or GLAS more profitable?

Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Glass House Brands N/A N/A N/A

Which has stronger earnings and valuation, GLAS or ATAI?

Glass House Brands has higher earnings, but lower revenue than Atai Beckley. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glass House Brands N/A N/A N/A N/A N/A Atai Beckley $4.09M 666.46 -$660.05M -$2.18 N/A

Which has better earnings & valuation, GLAS or GPCR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glass House Brands N/A N/A N/A N/A N/A Structure Therapeutics N/A N/A -$141.20M -$1.00 N/A

Is GLAS or GPCR more profitable?

Glass House Brands' return on equity of 0.00% beat Structure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Glass House Brands N/A N/A N/A Structure Therapeutics N/A -25.56% -24.31%

Does the media prefer GLAS or GPCR?

In the previous week, Structure Therapeutics had 2 more articles in the media than Glass House Brands. MarketBeat recorded 3 mentions for Structure Therapeutics and 1 mentions for Glass House Brands. Glass House Brands' average media sentiment score of 1.10 beat Structure Therapeutics' score of 0.25 indicating that Glass House Brands is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glass House Brands 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, GLAS or MLYS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glass House Brands N/A N/A N/A N/A N/A Mineralys Therapeutics N/A N/A -$154.65M -$4.24 N/A

Is GLAS or MLYS more profitable?

Glass House Brands' return on equity of 0.00% beat Mineralys Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Glass House Brands N/A N/A N/A Mineralys Therapeutics N/A -57.97% -54.15%

Does the media refer more to GLAS or MLYS?

In the previous week, Mineralys Therapeutics had 2 more articles in the media than Glass House Brands. MarketBeat recorded 3 mentions for Mineralys Therapeutics and 1 mentions for Glass House Brands. Glass House Brands' average media sentiment score of 1.10 beat Mineralys Therapeutics' score of 0.57 indicating that Glass House Brands is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glass House Brands 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Glass House Brands (GLAS) Competitors

$7.87 -0.10 (-1.25%)

As of 12:33 PM Eastern

Compare

GLAS vs. MOR, RGC, ATAI, GPCR, and MLYS

Should you buy Glass House Brands stock or one of its competitors? Glass House Brands's main competitors and comparable companies include MorphoSys (MOR), Regencell Bioscience (RGC), Atai Beckley (ATAI), Structure Therapeutics (GPCR), and Mineralys Therapeutics (MLYS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Glass House Brands compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Glass House Brands (NYSE:GLAS) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

Glass House Brands has lower revenue, but higher earnings than MorphoSys.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Glass House Brands	N/A	N/A	N/A	N/A	N/A

In the previous week, Glass House Brands had 1 more articles in the media than MorphoSys. MarketBeat recorded 1 mentions for Glass House Brands and 0 mentions for MorphoSys. Glass House Brands' average media sentiment score of 1.10 beat MorphoSys' score of 0.00 indicating that Glass House Brands is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Glass House Brands	Positive

Glass House Brands has a consensus target price of $16.00, suggesting a potential upside of 103.30%. Given Glass House Brands' stronger consensus rating and higher probable upside, analysts clearly believe Glass House Brands is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

18.4% of MorphoSys shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Glass House Brands has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Glass House Brands' return on equity of 0.00% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Glass House Brands	N/A	N/A	N/A

Summary

Glass House Brands beats MorphoSys on 8 of the 11 factors compared between the two stocks.

How does Glass House Brands compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Glass House Brands (NYSE:GLAS) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Glass House Brands	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Glass House Brands	N/A	N/A	N/A

0.1% of Regencell Bioscience shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Glass House Brands had 1 more articles in the media than Regencell Bioscience. MarketBeat recorded 1 mentions for Glass House Brands and 0 mentions for Regencell Bioscience. Glass House Brands' average media sentiment score of 1.10 beat Regencell Bioscience's score of 0.00 indicating that Glass House Brands is being referred to more favorably in the news media.

Company	Overall Sentiment
Regencell Bioscience	Neutral
Glass House Brands	Positive

Glass House Brands has a consensus price target of $16.00, suggesting a potential upside of 103.30%. Given Glass House Brands' stronger consensus rating and higher probable upside, analysts clearly believe Glass House Brands is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Glass House Brands beats Regencell Bioscience on 5 of the 7 factors compared between the two stocks.

How does Glass House Brands compare to Atai Beckley?

Glass House Brands (NYSE:GLAS) and Atai Beckley (NASDAQ:ATAI) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, Glass House Brands had 1 more articles in the media than Atai Beckley. MarketBeat recorded 1 mentions for Glass House Brands and 0 mentions for Atai Beckley. Glass House Brands' average media sentiment score of 1.10 beat Atai Beckley's score of 0.10 indicating that Glass House Brands is being referred to more favorably in the media.

Company	Overall Sentiment
Glass House Brands	Positive
Atai Beckley	Neutral

28.4% of Atai Beckley shares are held by institutional investors. 19.8% of Atai Beckley shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Glass House Brands has higher earnings, but lower revenue than Atai Beckley.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glass House Brands	N/A	N/A	N/A	N/A	N/A
Atai Beckley	$4.09M	666.46	-$660.05M	-$2.18	N/A

Glass House Brands currently has a consensus price target of $16.00, suggesting a potential upside of 103.30%. Atai Beckley has a consensus price target of $10.56, suggesting a potential upside of 43.62%. Given Glass House Brands' higher probable upside, equities research analysts plainly believe Glass House Brands is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06

Glass House Brands has a net margin of 0.00% compared to Atai Beckley's net margin of -14,938.36%. Glass House Brands' return on equity of 0.00% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glass House Brands	N/A	N/A	N/A
Atai Beckley	-14,938.36%	-88.30%	-58.88%

Summary

Glass House Brands beats Atai Beckley on 7 of the 12 factors compared between the two stocks.

How does Glass House Brands compare to Structure Therapeutics?

Glass House Brands (NYSE:GLAS) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

91.8% of Structure Therapeutics shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Structure Therapeutics had 2 more articles in the media than Glass House Brands. MarketBeat recorded 3 mentions for Structure Therapeutics and 1 mentions for Glass House Brands. Glass House Brands' average media sentiment score of 1.10 beat Structure Therapeutics' score of 0.25 indicating that Glass House Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glass House Brands	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Glass House Brands presently has a consensus target price of $16.00, suggesting a potential upside of 103.30%. Structure Therapeutics has a consensus target price of $110.91, suggesting a potential upside of 211.97%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Glass House Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glass House Brands	N/A	N/A	N/A	N/A	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

Glass House Brands' return on equity of 0.00% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glass House Brands	N/A	N/A	N/A
Structure Therapeutics	N/A	-25.56%	-24.31%

Summary

Structure Therapeutics beats Glass House Brands on 7 of the 10 factors compared between the two stocks.

How does Glass House Brands compare to Mineralys Therapeutics?

Glass House Brands (NYSE:GLAS) and Mineralys Therapeutics (NASDAQ:MLYS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glass House Brands	N/A	N/A	N/A	N/A	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A

Glass House Brands' return on equity of 0.00% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glass House Brands	N/A	N/A	N/A
Mineralys Therapeutics	N/A	-57.97%	-54.15%

Glass House Brands presently has a consensus price target of $16.00, suggesting a potential upside of 103.30%. Mineralys Therapeutics has a consensus price target of $48.80, suggesting a potential upside of 73.65%. Given Glass House Brands' higher possible upside, equities research analysts plainly believe Glass House Brands is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mineralys Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Mineralys Therapeutics had 2 more articles in the media than Glass House Brands. MarketBeat recorded 3 mentions for Mineralys Therapeutics and 1 mentions for Glass House Brands. Glass House Brands' average media sentiment score of 1.10 beat Mineralys Therapeutics' score of 0.57 indicating that Glass House Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glass House Brands	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mineralys Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.5% of Mineralys Therapeutics shares are owned by institutional investors. 18.9% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Mineralys Therapeutics beats Glass House Brands on 5 of the 9 factors compared between the two stocks.

Get Glass House Brands News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLAS vs. The Competition

Export

Metric	Glass House Brands	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$739.24M	$12.50B	$7.26B	$23.12B
Dividend Yield	N/A	2.64%	2.57%	3.62%
P/E Ratio	N/A	794.83	275.26	28.30
Price / Sales	N/A	799.22	697.68	95.93
Price / Cash	N/A	15.08	28.04	19.33
Price / Book	N/A	10.56	10.52	4.73
Net Income	N/A	$2.82B	$3.49B	$1.07B
7 Day Performance	-2.66%	-0.05%	-0.07%	-0.95%
1 Month Performance	-20.10%	-0.64%	-2.52%	-4.02%
1 Year Performance	N/A	4.16%	18.47%	8.71%

Glass House Brands Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLAS Glass House Brands	3.4583 of 5 stars	$7.87 -1.3%	$16.00 +103.3%	N/A	$739.24M	N/A	N/A	357	Positive News
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
RGC Regencell Bioscience	0.1489 of 5 stars	$5.76 +1.4%	N/A	-63.0%	$2.85B	N/A	N/A	10
ATAI Atai Beckley	2.7284 of 5 stars	$7.35 flat	$10.56 +43.6%	N/A	$2.73B	$4.09M	N/A	80	News Coverage
GPCR Structure Therapeutics	2.6632 of 5 stars	$36.16 +1.8%	$110.91 +206.8%	+48.4%	$2.53B	N/A	N/A	281	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GLAS) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Glass House Brands (GLAS) Competitors

GLAS vs. MOR, RGC, ATAI, GPCR, and MLYS

How does Glass House Brands compare to MorphoSys?

Summary

How does Glass House Brands compare to Regencell Bioscience?

Summary

How does Glass House Brands compare to Atai Beckley?

Summary

How does Glass House Brands compare to Structure Therapeutics?

Summary

How does Glass House Brands compare to Mineralys Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLAS vs. The Competition

Glass House Brands Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Glass House Brands (GLAS) Competitors

GLAS vs. MOR, RGC, ATAI, GPCR, and MLYS

How does Glass House Brands compare to MorphoSys?

Which has stronger valuation & earnings, MOR or GLAS?

Does the media refer more to MOR or GLAS?

Do analysts prefer MOR or GLAS?

Do insiders and institutionals hold more shares of MOR or GLAS?

Is MOR or GLAS more profitable?

Summary

How does Glass House Brands compare to Regencell Bioscience?

Which has stronger valuation and earnings, RGC or GLAS?

Is RGC or GLAS more profitable?

Do institutionals & insiders hold more shares of RGC or GLAS?

Does the media favor RGC or GLAS?

Do analysts recommend RGC or GLAS?

Summary

How does Glass House Brands compare to Atai Beckley?

Does the media favor GLAS or ATAI?

Do insiders and institutionals hold more shares of GLAS or ATAI?

Which has stronger earnings and valuation, GLAS or ATAI?

Do analysts recommend GLAS or ATAI?

Is GLAS or ATAI more profitable?

Summary

How does Glass House Brands compare to Structure Therapeutics?

Do insiders & institutionals hold more shares of GLAS or GPCR?

Does the media prefer GLAS or GPCR?

Do analysts recommend GLAS or GPCR?

Which has better earnings & valuation, GLAS or GPCR?

Is GLAS or GPCR more profitable?

Summary

How does Glass House Brands compare to Mineralys Therapeutics?

Which has better earnings & valuation, GLAS or MLYS?

Is GLAS or MLYS more profitable?

Do analysts recommend GLAS or MLYS?

Does the media refer more to GLAS or MLYS?

Do insiders and institutionals hold more shares of GLAS or MLYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLAS vs. The Competition

Glass House Brands Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools